Cumberland Pharmaceuticals Stock Analysis

CPIX Stock  USD 1.40  0.03  2.19%   
Cumberland Pharmaceuticals is undervalued with Real Value of 3.1 and Target Price of 8.5. The main objective of Cumberland Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Cumberland Pharmaceuticals is worth, separate from its market price. There are two main types of Cumberland Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Cumberland Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cumberland Pharmaceuticals is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Cumberland Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

Cumberland Stock Analysis Notes

About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cumberland Pharmaceuticals recorded a loss per share of 0.76. The entity last dividend was issued on the 29th of October 2010. The firm had 2:1 split on the 6th of July 2007. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceu operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more info on Cumberland Pharmaceuticals please contact the company at 615 255 0068 or go to https://www.cumberlandpharma.com.

Cumberland Pharmaceuticals Quarterly Total Revenue

9.09 Million

Cumberland Pharmaceuticals Investment Alerts

Cumberland Pharmaceuticals may become a speculative penny stock
Cumberland Pharmaceuticals had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 39.55 M. Net Loss for the year was (6.28 M) with profit before overhead, payroll, taxes, and interest of 32.89 M.
Cumberland Pharmaceuticals has a strong financial position based on the latest SEC filings
About 45.0% of the company shares are held by company insiders
Latest headline from thelincolnianonline.com: StockNews.com Initiates Coverage on Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Cumberland Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
5th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Cumberland Largest EPS Surprises

Earnings surprises can significantly impact Cumberland Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-05-20
2020-03-310.020.01-0.0150 
2012-11-01
2012-09-300.090.10.0111 
2012-02-29
2011-12-310.050.04-0.0120 
View All Earnings Estimates

Cumberland Pharmaceuticals Thematic Classifications

In addition to having Cumberland Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Drugs Idea
Drugs
Drug manufacturing and delivery
Health Management Idea
Health Management
Healthcare providers, hospitals

Cumberland Stock Institutional Investors

Shares
Schonfeld Strategic Advisors Llc2024-09-30
10 K
Ubs Group Ag2024-06-30
6.9 K
Tower Research Capital Llc2024-06-30
6.6 K
Morgan Stanley - Brokerage Accounts2024-06-30
5.3 K
Oakworth Capital Inc2024-09-30
3.1 K
Advisor Group Holdings, Inc.2024-06-30
100.0
Bank Of America Corp2024-06-30
67.0
Royal Bank Of Canada2024-06-30
47.0
Jpmorgan Chase & Co2024-06-30
20.0
Renaissance Technologies Corp2024-09-30
528.2 K
Vanguard Group Inc2024-09-30
374.3 K
Note, although Cumberland Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cumberland Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.66 M.

Cumberland Profitablity

The company has Profit Margin (PM) of (0.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.19.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.11)(0.10)
Return On Capital Employed(0.12)(0.11)
Return On Assets(0.08)(0.07)
Return On Equity(0.21)(0.20)

Management Efficiency

Cumberland Pharmaceuticals has return on total asset (ROA) of (0.0564) % which means that it has lost $0.0564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3607) %, meaning that it created substantial loss on money invested by shareholders. Cumberland Pharmaceuticals' management efficiency ratios could be used to measure how well Cumberland Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.11 in 2024. At this time, Cumberland Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 60.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 27.5 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 2.05  2.62 
Tangible Book Value Per Share 0.40  0.38 
Enterprise Value Over EBITDA 167.64  176.02 
Price Book Value Ratio 0.86  0.82 
Enterprise Value Multiple 167.64  176.02 
Price Fair Value 0.86  0.82 
Enterprise Value29.6 M28.1 M
The operational strategies employed by Cumberland Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Operating Margin
(0.19)
Profit Margin
(0.30)
Beta
0.219
Return On Assets
(0.06)
Return On Equity
(0.36)

Technical Drivers

As of the 1st of December, Cumberland Pharmaceuticals shows the Mean Deviation of 2.19, risk adjusted performance of 0.03, and Downside Deviation of 2.86. Cumberland Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cumberland Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cumberland Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cumberland Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Cumberland Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cumberland Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cumberland Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cumberland Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.32 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.23 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.26 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.28 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.3 subject to Rule 16b-3
 
Young Caroline over a month ago
Acquisition by Young Caroline of tradable shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3
 
Krogulski Kenneth over two months ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3

Cumberland Pharmaceuticals Outstanding Bonds

Cumberland Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cumberland Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cumberland bonds can be classified according to their maturity, which is the date when Cumberland Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Cumberland Pharmaceuticals Predictive Daily Indicators

Cumberland Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cumberland Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cumberland Pharmaceuticals Forecast Models

Cumberland Pharmaceuticals' time-series forecasting models are one of many Cumberland Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cumberland Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Cumberland Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cumberland Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cumberland shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cumberland Pharmaceuticals. By using and applying Cumberland Stock analysis, traders can create a robust methodology for identifying Cumberland entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.16)(0.15)
Operating Profit Margin(0.16)(0.15)
Net Loss(0.16)(0.15)
Gross Profit Margin 0.85  0.94 

Current Cumberland Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cumberland analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cumberland analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
8.5Strong Buy1Odds
Cumberland Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cumberland analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cumberland stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cumberland Pharmaceuticals, talking to its executives and customers, or listening to Cumberland conference calls.
Cumberland Analyst Advice Details

Cumberland Stock Analysis Indicators

Cumberland Pharmaceuticals stock analysis indicators help investors evaluate how Cumberland Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cumberland Pharmaceuticals shares will generate the highest return on investment. By understating and applying Cumberland Pharmaceuticals stock analysis, traders can identify Cumberland Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow19.8 M
Long Term Debt12.8 M
Common Stock Shares Outstanding14.3 M
Total Stockholder Equity29.6 M
Tax Provision69 K
Property Plant And Equipment NetM
Cash And Short Term Investments18.3 M
Cash18.3 M
Accounts Payable14 M
Net Debt106.9 K
50 Day M A1.2148
Total Current Liabilities28 M
Other Operating Expenses45.5 M
Non Current Assets Total46.1 M
Non Currrent Assets Other15.5 M
Stock Based Compensation365 K

Additional Tools for Cumberland Stock Analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.